Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | Carotid Angioplasty | Carotid Endarterectomy | Clinical Trials | Databases & Libraries | Epidemiology | Heart | Heart Attack | Norvir | Prezista | Stroke | Study